# CJC-1295 side effects and safety signals in the research record > CJC-1295 side effects and safety signals: no large human dataset, a discontinued DAC program, fluid retention, IGF-1/cancer epidemiology and an FDA immunogenicity note. What the limited record shows, what it leaves blank, and the regulatory concerns on file — stated plainly, with the gaps left visible. ## What the safety record does and does not show CJC-1295 side effects are not well characterized in healthy adults, and that absence is itself the most important finding. Published human exposure is limited to early pharmacokinetic studies; there is no controlled adverse-event dataset, no large efficacy trial, and no long-term safety data [7]. The long-acting DAC clinical program was discontinued, and CJC-1295 remains an unapproved research chemical [7]. This page is therefore unavoidably a page about uncertainty. A responsible reading of the CJC-1295 side-effect picture starts by refusing to invent a safety profile the studies never produced. The early PK trials were designed to measure GH and IGF-1 kinetics in small groups of healthy volunteers, not to detect rare or delayed harms, and no later trial filled that gap [1][3][7]. So the most accurate framing is not 'CJC-1295 is safe' or 'CJC-1295 is dangerous' — it is that the human safety question has not been answered, and the signals that exist are inferred rather than measured. What can be said comes from the mechanism and from class-level concerns. Stimulating the GH/IGF-1 axis can cause fluid retention and edema, and GH-axis activity has effects on insulin sensitivity [14]. Epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers, which is a theoretical concern whenever IGF-1 is raised sustainedly [14]. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity — the potential for synthetic peptides to provoke anti-drug antibodies — alongside other safety concerns [13]. ### Is CJC-1295 safe? There is no large human safety dataset. The long-acting DAC program was discontinued, sustained GH/IGF-1 elevation raises theoretical concerns (fluid retention, IGF-1/cancer epidemiology), and the FDA flagged immunogenicity [13][14]. It remains an unapproved research chemical with no approved indication anywhere [7]. ### Are CJC-1295 peptides safe? Published human exposure is limited to early PK studies; there is no long-term safety dataset, the DAC clinical program was halted, and the FDA flagged immunogenicity [13][7]. CJC-1295 is an unapproved research chemical, and claims of an established safety profile in healthy adults are not supported by the peer-reviewed record. ## Reported and theoretical effects The discontinuation of the DAC program is part of the safety story. A ConjuChem Phase 2 trial of CJC-1295 DAC in HIV-associated visceral obesity (NCT00267527) was halted, and a patient death during the development era is frequently cited in connection with the stopped program, though a causal link to CJC-1295 was not established in the public record [7]. That uncertainty is exactly why the event is reported here as cited-but-unproven rather than as a confirmed adverse effect — overstating it would be as misleading as ignoring it. It is worth separating the two categories of concern. The first is mechanistic and class-level: anything that sustainedly raises GH and IGF-1 inherits the known consequences of GH-axis activity, including fluid retention, edema, and effects on insulin sensitivity, plus the epidemiological association between higher IGF-1 and modestly increased risk of certain cancers [14]. The second is regulatory: the FDA's 2024 advisory briefing singled out immunogenicity for GH secretagogues including CJC-1295, a recognized risk for synthetic peptide therapeutics generally [13]. Neither category is the same as a measured adverse-event rate from a dedicated CJC-1295 safety trial — because no such trial exists. The most accurate thing the record supports is a careful statement of what is plausible and what is simply unknown. This is also where the regulatory picture and the safety picture meet. The FDA's decision not to recommend CJC-1295 for the 503A compounding bulks list, and its citation of immunogenicity in doing so, is not a separate bureaucratic fact — it reflects the same thin evidence base described here [13]. A compound studied only in small early-phase groups, with a discontinued long-acting program behind it, is exactly the kind of substance a regulator flags rather than clears [7][13]. The honest gaps on this page and the regulatory caution elsewhere are two views of one underlying reality. ### What are the side effects of CJC-1295? There is no controlled adverse-event dataset in healthy adults [7]. GH-axis stimulation can cause fluid retention and edema; theoretical concerns include effects on insulin sensitivity and the IGF-1/cancer epidemiology, and the FDA cited immunogenicity [13][14]. Reported effects are inferred from mechanism and class, not from a dedicated safety trial of CJC-1295. ### Does CJC affect testosterone? CJC-1295 acts on the GH/IGF-1 axis, which is distinct from the gonadal (testosterone) axis [2]. Published CJC-1295 studies measured GH and IGF-1, not androgens, and did not characterize it as a testosterone-altering agent [3]. There is no evidence in the compound's literature that it raises or lowers testosterone. ### Does CJC-1295 lower testosterone? No published CJC-1295 study reports it as a testosterone-lowering agent; its target is the GH/IGF-1 axis [2][3]. Claims that it raises or lowers testosterone are not supported by the peer-reviewed literature on the compound, which measured GH and IGF-1 rather than gonadal hormones. --- A plain-language information sheet on the CJC-1295 record — every finding and every regulatory status set down so it reads in full even in grayscale, with no clinic behind the sheet and nothing here prescribed or sold.